What Happened

Scholar Rock reported Q2 2026 financial results, with a net loss of $109.9M. The company highlighted progress in FDA review of apitegromab for SMA, with two fill-finish facilities providing independent paths to approval by September 30, 2026. Data for the second facility has been submitted, and commercialization supply is secured.

Who Is Affected

Scholar Rock's leadership, investors, and commercial teams are preparing for a potential U.S. launch. SMA patients and clinicians await the first muscle-targeted treatment. Regulatory bodies (FDA, EMA) and manufacturing partners (Catalent Indiana LLC, Novo Nordisk) are actively engaged in the approval process.

Market Impact

• First-ever myostatin inhibitor approval would disrupt SMA treatment landscape
• Scholar Rock has $492M in cash, positioning it for commercialization
• Phase 2 FSHD study expands addressable market beyond SMA

What to Watch

FDA decision on apitegromab by September 30, 2026. EMA engagement for European approval. Results from Phase 2 FORGE study in FSHD. Scholar Rock's ability to execute launch with two manufacturing pathways.

Related coverage

• FDA approves Revolution Medicines' daraxonrasib for advanced pancreatic cancer
• FDA Accepts NDA for Apnimed's Sleep Apnea Pill AD109
• Longeveron's Laromestrocel reduces neuroinflammation in Alzheimer's patients
• 6-Month RR-TB Trial as a Pragmatic Design Blueprint